Search
KC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascula...
Mericitabine
go.drugbank.com/drugs/DB12045InvestigationalMericitabine is a prodrug of PSI-6130, which demonstrated excellent potency in preclinical studies. … PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for hepatitis C viral replication.
Fenbufen
go.drugbank.com/drugs/DB08981ApprovedFenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis.
Interferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnInterferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. … The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding
Loprazolam
go.drugbank.com/drugs/DB13643ExperimentalIt is not an FDA-approved drug. … Loprazolam is an imidazobenzodiazepine with anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.
Chlorophyll B
go.drugbank.com/drugs/DB04506Experimental(From Dorland, 27th ed) … It is a component of both intra- and extracellular fluids and is excreted in the urine and feces.
Amcipatricin
go.drugbank.com/drugs/DB12333InvestigationalIn preclinical models, SPK-843 shows in vitro inhibitory activity comparable to or better than that of Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. … SPK-843 exhibits dose-dependent efficacy on murine pulmonary aspergillosis models.
Imgatuzumab
go.drugbank.com/drugs/DB14884InvestigationalImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With
Alobresib
go.drugbank.com/drugs/DB14970InvestigationalAlobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants